Investor Relations

Advanced therapies for the sports medicine and severe burn care markets

Day High:
Day Low:
Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Relations

Press Releases

September 28, 2023

Vericel Announces Publication of Positive Results from Phase 3 Debride and Protect (DETECT) Study of Thermal Burn Patients Treated with NexoBrid

September 20, 2023

Vericel Announces U.S. Commercial Availability of NexoBrid® (anacaulase-bcdb) for the Treatment of Severe Thermal Burns in Adults

September 6, 2023

Vericel to Present at the Morgan Stanley Global Healthcare Conference

Events and Presentations

Upcoming Events
More events are coming soon.



More information is coming soon.

Stock Quote & Analyst Coverage

Stock Quote ()

Today's Open
Previous Close
Today's High
Today's Low
52 Week High
52 Week Low
Vericel Corporation is covered by the following analysts.
Ryan Zimmerman
Swayampakula Ramakanth
H.C. Wainwright & Co.
Jeff Cohen
Ladenburg Thalmann
George Sellers
Samuel Brodovsky

Vericel Corporation is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Vericel Corporation's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Vericel Corporation or its management. Vericel Corporation does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.